Publications To Date


    Filter Publications

    PAGE 1 OF 12 | DISPLAYING 1 - 15 OF 173 RESULTS

    Bommareddy P.K. et. al., MEK inhibition enhances oncolytic virus immunotherapy through increased tumor cell killing and T cell activation, 10.1126/scitranslmed.aau0417 , Science, Dec 12, 2018

    Chon H.J. et. al., Tumor microenvironment remodeling by intratumoral oncolytic vaccinia virus enhances the efficacy of immune checkpoint blockade., 10.1158/1078-0432.CCR-18-1932, Clin. Can. Res., Dec 11, 2018

    Grabosch S. et. al., Cisplatin-induced immune modulation in ovarian cancer mouse models with distinct inflammation profiles,, Oncogene, Dec 05, 2018

    Freedman J.D. et. al., An Oncolytic Virus Expressing a T-cell Engager Simultaneously Targets Cancer and Immunosuppressive Stromal Cells, 10.1158/0008-5472.CAN-18-1750, Cancer Res., Dec 01, 2018

    Christmas B.J. et. al., Entinostat Converts Immune-Resistant Breast and Pancreatic Cancers into Checkpoint-Responsive Tumors by Reprogramming Tumor-Infiltrating MDSCs, 10.1158/2326-6066.CIR-18-0070, Can. Immunol. Res., Dec 01, 2018

    Gomes B. et. al., Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy, 10.1158/1535-7163.MCT-17-1104, Mol. Can. Ther., Dec 01, 2018

    Fenerty K.E. et. al., Immunotherapy utilizing the combination of natural killer– and antibody dependent cellular cytotoxicity (ADCC)–mediating agents with poly (ADP-ribose) polymerase (PARP) inhibition, 10.1186/s40425-018-0445-4, J. Immunother. Cancer, Nov 29, 2018

    Smith H.J. et. al., The antitumor effects of entinostat in ovarian cancer require adaptive immunity., 10.1002/cncr.31761, Cancer, Nov 13, 2018

    Yu J.W. et. al., Tumor-immune profiling of murine syngeneic tumor models as a framework to guide mechanistic studies and predict therapy response in distinct tumor microenvironments, 10.1371/journal.pone.0206223, PLoS ONE, Nov 02, 2018

    Du W. et. al., Sitravatinib potentiates immune checkpoint blockade in refractory cancer models, 10.1172/jci.insight.124184, JCI Insight, Nov 02, 2018

    Szekely B. et. al., Immunological differences between primary and metastatic breast cancer., doi: 10.1093/annonc/mdy399., Ann. Oncol., Nov 01, 2018

    Mukhopadhyay A. et. al., Characterization of abscopal effects of intratumoral electroporation-mediated IL-12 gene therapy,, Gene Therapy, Oct 15, 2018

    Cristescu R. et. al., Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy, 10.1126/science.aar3593 , Science, Oct 12, 2018

    Angelova M. et. al., Evolution of Metastases in Space and Time under Immune Selection,, Cell, Oct 11, 2018

    Medler T.R. et. al., Complement C5a Fosters Squamous Carcinogenesis and Limits T Cell Response to Chemotherapy,, Cancer Cell, Oct 08, 2018